美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · LBRX近 30 天 4 則 · 第 1 / 1 頁
- LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
- IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
- 2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment
- LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
- LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- LB Pharmaceuticals Announces $150 Million Private Placement
- LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
- Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls
- LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
- LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential
- LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
- Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
- LB Pharmaceuticals to Participate in Upcoming June Investor Events
- All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
- LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans
- LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
- LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
- LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham
- LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。